Early diagnostic biomarkers of Lung cancer; a review study

Abstract

Lung cancer is the main cause of cancer-related death. Typically, lung cancer has been classified in two histologic types; small and non-small cell (NSC), with adenocarcinoma, squamous cell form and large cell type. The availability of predictive biomarkers for the treatment of NSC lung cancer (NSCLC) has been changed in recent decades, especially in the form of adenocarcinoma. Controlling for sensitizing mutations inside the epidermal growth factor receptor (EGFR) for patients with advanced adenocarcinomas is currently needed before the achievement of anti-EGFR inhibitors (such as erlotinib, gefitinib, afatinib or osimertinib). In a patient with no signs of tumor tissue, the EGFR mutational plasma and urine examination may be performed. ALK gene rearrangement research is required to predict crizotinib reaction. Treatment with ceritinib, alectinib or brigatinib also relies on ALK rearrangements. PD-L1 should be tested with an approved assay to model reactions in patients with advanced adenocarcinoma or squamous cell NSCLCs to the single pembrolizumab agent in their first-line therapy. As miRNAs are a vital biomarker (diagnostic biomarkers), miRNAs also could be used as a dynamic tumor predictor before and during therapy because of their function in carcinogenesis at all stages. Nevertheless, lncRNA sheds fresh insight into our tumor pathway perception. In biomedicine, lncRNA is intensely involved, which can be used for a wide variety of cancers as a clinical diagnostic and prediction predictor.

Authors and Affiliations

Mostafa Khafaei; Ali Miri; Ebrahim Kiani; Elham Danesh; Mehdi Naderi

Keywords

Related Articles

Evaluation of antimicrobial activity of essential oil of Pistacia khinjuk in Iran

Today, with increasing prevalence antibiotic resistance monitoring the health and quality of food has become complicated and difficult. Therefore, essential oils of medicinal plants is significant and the investigation...

Medicinal plants as a hopeful therapeutic approach against COVID-19 infection

The disease of COVID-19 is generated by the SARS-COV-2 virus and principally attacks the lung tissue. In addition, other tissues are also attacked by the virus. Reports have shown that the clinical symptoms of this disea...

C3953T genetic variation in interleukin 1β and idiopathic male infertility: a systematic review and meta-analysis

According to the World Health Organization, infertility means that a couple will not have children after 12 months of unprotected sex. Half of all cases of infertility are due to male factors. Environmental and genetic f...

Role of ESR1 PvuII T/C variant in female reproductive process: A review

Estrogen hormone is involved in the process of reproduction by banding to estrogen receptors (ERs). The findings of previous studies showed the association of a common variant, PvuII T/C (rs 2234693), in ESR1 gene with d...

Non-coding RNAs and their role in Alzheimer's pathogenesis

Alzheimer's disease is a progressive and irreversible brain disorder. This disease is the most common reason for dementia in aged people. Pathological symptoms of this disease are the formation of beta-amyloid plaques an...

Download PDF file
  • EP ID EP714353
  • DOI 10.22034/CAJMPSI.2021.03.02
  • Views 71
  • Downloads 0

How To Cite

Mostafa Khafaei; Ali Miri; Ebrahim Kiani; Elham Danesh; Mehdi Naderi (2021). Early diagnostic biomarkers of Lung cancer; a review study. Central Asian Journal of Medical and Pharmaceutical Sciences Innovation, 1(3), -. https://europub.co.uk/articles/-A-714353